AN0025 + paclitaxel + carboplatin

AN0025 + paclitaxel + carboplatin is a combination regimen under investigation for cancer therapy, combining three active agents: - **AN0025 (palupiprant, formerly E7046):** a small molecule, oral, selective prostaglandin E2 receptor 4 (EP4) antagonist that blocks the immunosuppressive signaling of prostaglandin E2, thereby modulating the tumor microenvironment and potentially enhancing antitumor immune responses[1][3][5][7]. - **Paclitaxel:** a microtubule-stabilizing agent that inhibits mitosis, widely used as a cytotoxic chemotherapeutic in various carcinomas including ovarian, breast, and lung cancers[2][4][8][10]. - **Carboplatin:** a platinum-based DNA crosslinker that causes apoptosis in rapidly proliferating cells, also a standard chemotherapeutic in many solid tumors[2][4][8][10]. This combination is being tested in the neoadjuvant or definitive chemoradiotherapy setting for locally advanced rectal, esophageal, and esophagogastric junction cancers[5][7][9]. AN0025 is developed by Adlai Nortye, who licensed it from Eisai[1][7].

Other names

palupiprant + paclitaxel + carboplatin